

CATALYST PHARMACEUTICAL PARTNERS, INC.

Form 8-K

September 07, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

September 6, 2011

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)

Commission File No. 001-33057

CATALYST PHARMACEUTICAL
PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

Delaware (State Or Other Jurisdiction	76-0837053 (IRS Employer
Of Incorporation Or Organization)	Identification No.)
355 Alhambra Circle, Suite 1370	
Coral Gables, Florida 33134	
(Address Of Principal Executive Offices)	
(305) 529-2522	
(Registrant's Telephone Number, Including Area Code)	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On September 6, 2011, Philip Coelho, one of the Company's outside independent directors, advised the Company that he has sold 216,546 shares of the Company's common stock in the open market. Mr. Coelho further advised the Company that his shares were purchased by one of the Company's existing institutional investors. Finally, Mr. Coelho advised the Company that his sale of shares related to a need to raise funds in order to capitalize a private business venture and did not relate to any disagreements with the Company on any matter relating to the Company's operations, policies and practices. Mr. Coelho remains a shareholder and a director of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceutical Partners, Inc.

By: /s/ Patrick J. McEnany
Patrick J. McEnany
Chairman, President and CEO

Dated: September 7, 2011